報價延遲最少15分鐘:2024/11/16 08:59 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.68 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.84/--
|
|
企業價值
470.40M
|
| 資產負債 |
|
每股賬面淨值
7.00
|
| 現金流量 |
|
現金流量率
0.20
|
| 損益表 |
|
收益
572.43M
|
|
每股收益
22.39
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/16 08:59 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates,as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment. |